Mucinous Ovarian Carcinoma.
Morice P, Gouy S, Leary A.
N Engl J Med. 2019 Mar 28;380(13):1256-1266. doi: 10.1056/NEJMra1813254.
Mucinous Ovarian Tumors.
Mills AM, Shanes ED.
Surg Pathol Clin. 2019 Jun;12(2):565-585. doi: 10.1016/j.path.2019.01.008.
A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.
Yang L, Yu J, Zhang S, Shan Y, Li Y, Xu L, Zhang J, Zhang J.
J Ovarian Res. 2022 Feb 16;15(1):26. doi: 10.1186/s13048-022-00958-6.
Mucinous epithelial ovarian carcinoma.
Perren TJ.
Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57. doi: 10.1093/annonc/mdw087.
Molecular and immunohistochemical markers in appendiceal mucinous neoplasms: A systematic review and comparative analysis with ovarian mucinous neoplasms and colorectal adenocarcinoma.
Elsayed B, Elshoeibi AM, Elhadary M, Al-Jubouri AM, Al-Qahtani N, Vranic S, Al-Saady R.
Histol Histopathol. 2025 May;40(5):621-633. doi: 10.14670/HH-18-830. Epub 2024 Oct 10.
Mucinous ovarian cancer: A therapeutic review.
Xu W, Rush J, Rickett K, Coward JI.
Crit Rev Oncol Hematol. 2016 Jun;102:26-36. doi: 10.1016/j.critrevonc.2016.03.015. Epub 2016 Mar 19.
Recent Insights into Mucinous Ovarian Carcinoma.
Ricci F, Affatato R, Carrassa L, Damia G.
Int J Mol Sci. 2018 May 24;19(6):1569. doi: 10.3390/ijms19061569.
KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
Hershkovitz D, Vlodavsky E, Simon E, Ben-Izhak O.
Pathol Int. 2013 Dec;63(12):611-4. doi: 10.1111/pin.12123.
Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
Moioli M, Barra F, Maramai M, Valenzano Menada M, Vellone VG, Costantini S, Ferrero S.
Expert Opin Investig Drugs. 2019 Dec;28(12):1025-1029. doi: 10.1080/13543784.2019.1693999. Epub 2019 Nov 19.
Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach.
Talia KL, Parra-Herran C, McCluggage WG.
Histopathology. 2022 Jan;80(2):255-278. doi: 10.1111/his.14399. Epub 2021 Oct 20.
